Floatz logo

FENTANYL

Breakthrough Pain

CephalonSmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Breakthrough Pain cohort.

Asset / SponsorPhaseRating
NEPENTHE
University Hospitals Cleveland Medical Center
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
University Hospitals Cleveland Medical Center
Phase 4BB
Oxycodone
University Hospitals Cleveland Medical Center
Phase 4BB

Same molecule, other indications

FENTANYL is also rated in:

Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →
PainDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →